Profound Medical launches AI-powered TULSA-AI Volume Reduction module for BPH; TAM could triple to ~600K patients

Profound Medical Corp.

Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.
CEO Arun Menawat says module could triple total addressable market to ~600,000 patients annually.
CAPTAIN randomized trial data shows TULSA superior to robotic prostatectomy in blood loss, length of stay, and pain.
TULSA Procedure is the only incision-free therapy for both prostate cancer and BPH with customizable precision.
Profound to present new TULSA-PRO data at RSNA and SUO meetings through Dec 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.